Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial Article

Arrieta, Alejandro, Hong, Jonathan C, Khera, Rohan et al. (2017). Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial . JAMA CARDIOLOGY, 2(12), 1369-1374. 10.1001/jamacardio.2017.3655

Open Access

cited authors

  • Arrieta, Alejandro; Hong, Jonathan C; Khera, Rohan; Virani, Salim S; Krumholz, Harlan M; Nasir, Khurram

sustainable development goals

authors

publication date

  • December 1, 2017

published in

keywords

  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • DEATH
  • DISEASE
  • Life Sciences & Biomedicine
  • SURVIVAL
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER MEDICAL ASSOC

start page

  • 1369

end page

  • 1374

volume

  • 2

issue

  • 12